-
The maximum subsidy for Xi'an photovoltaic technology transformation project is 5 million yuan
Time of Update: 2022-11-24
The media reporter learned from the Xi'an Municipal Government on the 18th that Xi'an issued the "Implementation Opinions on Promoting the Sustainable and Healthy Development of the Photovoltaic Indu
-
Molex of the United States launches the Temp-Flex multi-core hybrid cable
Time of Update: 2022-11-21
” This Temp-Flex multicore hybrid cable can be used for audio/video, entertainment equipment, medical applications, aerospace and defense, including control centers, instrumentation, military vehicles, missiles, radar, satellites and vision systems.
-
China's first million-kilowatt-level photovoltaic leader base was officially connected to the grid for power generation
Time of Update: 2022-11-21
38 billion kWh. On June 29, the national advanced technology photovoltaic demonstration base in the Datong coal mining subsidence area, which has attracted much attention in the industry, was officially connected to the grid for power generation, which is also China's first million-kilowatt-level photovoltaic power generation leading demonstration base successfully connected to the grid and put into operation.
-
Issue 43/2015 - 12% of advanced composite materials for large aircraft in China
Time of Update: 2022-11-13
This not only marks the official completion of the docking of most sections of the body and the installation of the airborne system of the first C919 aircraft, which has reached the state of ground testing, but also marks that the development stage of the C919 large passenger aircraft project has achieved phased results, laying a solid foundation for the next first flight.
-
New Immune Cell Therapy Drug-Enhanced Cell Therapy Detailed Explanation
Time of Update: 2022-08-30
clinical researchAdvanced solid tumors (platinum-resistant ovarian cancer, endometrial cancer, cervical cancer) starting November 12, 2021NCT05107739 A Study of DeTIL-0255 in Adults With Advanced Malignancies ASCO PosterA phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies.
-
【WCLC】Broken cocoon and turned into a butterfly and reborn | Amivantamab combined with Lazertinib in the first-line treatment of patients with EGFR-sensitive mutation PFS may exceed 28 months
Time of Update: 2022-08-20
At present, the researchers are conducting a large-scale phase III study MARIPOSA to compare the efficacy and safety of the Amivantamab + Lazertinib regimen and the first-line treatment of osimertinib in patients with EGFR-sensitive mutated NSCLC, which is worth looking forward to .
-
How does the "king of cancer" help the early detection of pancreatic ductal adenocarcinoma
Time of Update: 2022-01-07
Recently, the team of Professor Yin Yuxin of Peking University School of Basic Medicine and the collaborators of the Chinese Academy of Sciences and the Chinese People’s Liberation Army General Hospital applied machine learning combined with lipidomics and multi-omics techniques to comprehensively analyze the metabolic characteristics of pancreatic ductal adenocarcinoma (pancreatic cancer), and developed artificial The intelligent-assisted PDAC serum metabolism detection method achieved 86.
-
Liver Cancer: Cabozantinib can safely and effectively treat compensated advanced liver cancer
Time of Update: 2021-09-03
This is an international, multi-center, real cohort study designed to evaluate the safety and effectiveness of cabozantinib in patients with advanced HCC .
Cabozantinib can effectively treat advanced HCC with compensated liver cirrhosis and has good safety.
-
China builds a global energy Internet to promote green and low-carbon development
Time of Update: 2021-06-24
Original source: Economic Information Daily In March 2016, the first international organization in the energy field initiated by China-the Global Energy Interconnection Development Cooperation Organi
-
ASCO annual meeting grand opening
Time of Update: 2021-06-12
According to reports, the RATIONALE 302 study is a randomized, open, multi-center, global phase 3 clinical trial designed to evaluate tislelizumab versus chemotherapy selected by investigators as the second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma Effectiveness and safety.
-
The principle of long-term multi-generation high temperature plant gene mutation revealed
Time of Update: 2021-05-31
This study revealed for the first time the DNA mutation rate and mutation spectrum laws of plants under long-term multi-generation high temperature from the two levels of population genetic pedigree and single seed genetic pedigree, and provided an important theoretical basis for elucidating the mechanism of plant molecular evolution under long-term environmental stress.
-
Cancers: Biomarkers for immunotherapy of advanced gastroesophageal cancer
Time of Update: 2021-05-31
In addition to tumor type-independent markers MSI and TMB, the only validated predictive biomarker for immunotherapy in GEC is PD-L1 CPS.
gov/33916348/" target="_blank" rel="noopener">Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond .
-
Demystified | Why does HPV negative cause cervical cancer
Time of Update: 2021-03-23
The pathological type of cervical adenocarcinoma and its HPV-positive rate FIGO staging HPV-negative cervical cancer patients are usually diagnosed as FIGO advanced stage with lymphatic and vascular space infiltration, leading to a poor prognosis.
-
Johnson and Johnson Amivantamab Dual Anti-Domestic Start-Up Phase III Clinical has submitted BLA to the FDA
Time of Update: 2020-12-22
addition, according to the Insight database, Johnson and Johnson registered six Amivantamab clinical trials at ClinicalTrials.gov, including two Phase III clinical trials, and in addition to taking drugs with Lazertinib, Johnson and Johnson explored Amivantamab's joint treatment with Capra/Pemite to treat NSCLC patients inserted by EGFR 20 exons.
-
A number of heavyweight varieties have been approved for listing, involving Gilead, AstraZeneta, Lilly
Time of Update: 2020-11-14
AstraZeneca/ First Three AstraZeneca / 13th Announced on the 26th that its jointly developed HER2 targeted antibody consonant drug (ADC) Enhertu extended adaptive disease has been approved by Japan's Ministry of Health, Labour, for the treatment of HER2 positive can not be removed in patients with advanced or relapsed stomach cancer.
